Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Gottfried von Keudell, MD PhD
- Target Recruit Count
- 33
- Registration Number
- NCT06510309
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT06508489
- Locations
- 🇺🇸
City of Hope National Medical Center- Site Number : 8400003, Duarte, California, United States
🇦🇺Investigational Site Number : 0360002, Wollongong, New South Wales, Australia
🇦🇺Investigational Site Number : 0360001, Melbourne, Victoria, Australia
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06504459
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
- Conditions
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT06496308
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, China
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 and ASTX727 With Venetoclax to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT06484062
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
- Conditions
- Interventions
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-07-01
- Target Recruit Count
- 82
- Registration Number
- NCT06481228
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
- Conditions
- Interventions
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-07-01
- Target Recruit Count
- 77
- Registration Number
- NCT06481241
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06471738
- Locations
- 🇨🇳
Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing, China
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Kerry Rogers
- Target Recruit Count
- 30
- Registration Number
- NCT06466122
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias
- Conditions
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06466395
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.